Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis C

Free Subscription Articles published in Clin Res Hepatol Gastroenterol Retrieve available abstracts of 22 articles: HTML format

Single Articles

October 2022
1. EL-KASSAS M, Elbehiry S, Rezk E, Omran D, et al
   Discontinuing Directly Acting Antivirals During Hepatitis C Treatment: Highlighting an Infrequent but Hostile Event.
   Clin Res Hepatol Gastroenterol. 2022 Oct 22:102042.
   PubMed    
   
   
   September 2022
2. COILLY A, Sebagh M, Fougerou-Leurent C, Pageaux GP, et al
   HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation.
   Clin Res Hepatol Gastroenterol. 2022 Sep 16:102024.
   PubMed     Abstract available
   
   
   August 2022
3. OKUMURA T, Joshita S, Sugiura A, Ota M, et al
   Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
   Clin Res Hepatol Gastroenterol. 2022 Aug 25:102011.
   PubMed    
   
   
   
4. YANG X, Wang N, Li S, Gu Y, et al
   No differences in the risk of Hepatocellular Carcinoma from Using Direct-Acting Antiviral Agents or Interferon in Patients with Chronic Hepatitis C: A meta-analysis.
   Clin Res Hepatol Gastroenterol. 2022 Aug 12:102001.
   PubMed    
   
   
   
5. CAROLE S, Elena L, Benedicte LV, Abdoul-Aziz D, et al
   Acute Myeloid Leukaemia following Direct Acting Antiviral drugs in HCV-infected patients: a 10 years' retrospective single-center study.
   Clin Res Hepatol Gastroenterol. 2022 Aug 3:102000.
   PubMed     Abstract available
   
   
   May 2022
6. DE CONTO F, Buttrini M, Dell'Anna ML, Maccari C, et al
   Detection of occult hepatitis B virus infection among subjects with isolated hepatitis B core antibodies: Results from a 3-year survey in an Italian tertiary-care hospital.
   Clin Res Hepatol Gastroenterol. 2022;46:101892.
   PubMed     Abstract available
   
   
   April 2022
7. AZZI J, Dorival C, Cagnot C, Fontaine H, et al
   Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
   Clin Res Hepatol Gastroenterol. 2022 Apr 8:101923.
   PubMed     Abstract available
   
   
   January 2022
8. KHALID SS, Abdo AA, Al-Hamoudi W, Alswat K, et al
   Association of mitotic checkpoint regulator MAD2L1 with fibrosis progression in chronic hepatitis C patients.
   Clin Res Hepatol Gastroenterol. 2022 Jan 6:101860.
   PubMed    
   
   
   December 2021
9. COLUCCI G, Renteria SU, Lunghi G, Ceriotti F, et al
   Italian Migrants Study: an HCV and HBV Micro-Elimination Pilot Project.
   Clin Res Hepatol Gastroenterol. 2021 Dec 16:101852.
   PubMed     Abstract available
   
   
   September 2021
10. CLEMENTE MG, Mauceri C, Grandi N, Marescalco S, et al
    No Hepatitis G virus co-infection in migrants with Hepatitis B or C hosted in Sardinia and Sicily.
    Clin Res Hepatol Gastroenterol. 2021;45:101566.
    PubMed    
    
    
    
11. GEROSSIER L, Dubois A, Paturel A, Fares N, et al
    PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?
    Clin Res Hepatol Gastroenterol. 2021;45:101553.
    PubMed     Abstract available
    
    
    July 2021
12. TRAN A, Shili-Masmoudi S, Moga L, Chevaliez S, et al
    NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS C VIRUS.
    Clin Res Hepatol Gastroenterol. 2021 Jul 28:101771.
    PubMed     Abstract available
    
    
    June 2021
13. EL-BARAKY IA, Abbassi MM, Ebied FS, Hassany M, et al
    Beta-Thalassemia Major alters Sofosbuvir/Ledipasvir exposure in Hepatitis-C virus Infected Adolescent Patients.
    Clin Res Hepatol Gastroenterol. 2021 Jun 26:101747.
    PubMed     Abstract available
    
    
    May 2021
14. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
    HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
    Clin Res Hepatol Gastroenterol. 2021;45:101608.
    PubMed    
    
    
    April 2021
15. NABATCHIKOVA EA, Abdurakhmanov DT, Rozina TP, Nikulkina EN, et al
    Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience.
    Clin Res Hepatol Gastroenterol. 2021 Apr 27:101714.
    PubMed     Abstract available
    
    
    
16. TREPO C
    THE 2020 NOBEL PRIZE OF MEDICINE FOR THREE HEPATITIS C DISCOVERY PIONEERS : A MEDICAL HISTORY MILESTONE.
    Clin Res Hepatol Gastroenterol. 2021 Apr 10:101689.
    PubMed    
    
    
    March 2021
17. AL-KHAYKANEE AM, Abdel-Rahman AA, Essa A, Gadallah AA, et al
    Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101636.
    PubMed     Abstract available
    
    
    
18. LAZARUS JV, Picchio CA, Guy D, Aleman S, et al
    Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy.
    Clin Res Hepatol Gastroenterol. 2021;45:101564.
    PubMed     Abstract available
    
    
    February 2021
19. ROGER S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, et al
    HCV virology and diagnosis.
    Clin Res Hepatol Gastroenterol. 2021;45:101626.
    PubMed     Abstract available
    
    
    
20. ROUDOT-THORAVAL F
    Epidemiology of hepatitis C virus infection.
    Clin Res Hepatol Gastroenterol. 2021;45:101596.
    PubMed     Abstract available
    
    
    November 2020
21. PARLATI L, Hollande C, Pol S
    Treatment of hepatitis C virus infection.
    Clin Res Hepatol Gastroenterol. 2020 Nov 30:101578.
    PubMed     Abstract available
    
    
    
22. BOLETO G, Vieira M, Saadoun D, Cacoub P, et al
    Hepatitis C virus-related vasculitis.
    Clin Res Hepatol Gastroenterol. 2020 Nov 29:101575.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: